LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

Kodu・Aktsiate loetelu・ADMA Biologics Inc

ADMA Biologics Inc

Suletud

Sektor Tervishoid

20.34 -1.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.3

Max

21.11

Põhinäitajad
By Trading Economics
Sissetulek	35M 18M
Müük	8M 82M
Aktsiakasum	0.08
Kasumimarginaal	21.748
Töötajad	624
EBITDA	7.9M 24M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	-6.71 downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2024

Turustatistika
By TradingEconomics
Turukapital	-71M 4.4B
Eelmine avamishind	22.27
Eelmine sulgemishind	20.34

Uudiste sentiment

By Acuity

22%

78%

55 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

19.8 / N/A Toetus ja vastupanu

ADMA Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2024, 23:44 UTC

Peamised uudised

Tulu

GM Met With Investors Tuesday. The Car Business Is Better Than Many Fear. -- Barrons.com

8. okt 2024, 23:12 UTC

Omandamised, ülevõtmised, äriostud

Woodside Completes Acquisition Of Tellurian >WDS.AU

8. okt 2024, 23:03 UTC

Peamised uudised

Federal Deficit Hit $1.8 Trillion for 2024, CBO Say -- 5th Update

8. okt 2024, 22:57 UTC

Peamised uudised

Federal Deficit Hit $1.8 Trillion for 2024, CBO Say -- 4th Update

8. okt 2024, 22:54 UTC

Market Talk

Tulu

PepsiCo's Promotional Approach at Core of Debate -- Market Talk

8. okt 2024, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Paladin: No Certainty Paladin Will Be Able to Obtain Investment Canada Act Clearance for Fission Uranium Deal

8. okt 2024, 22:37 UTC

Omandamised, ülevõtmised, äriostud

Paladin: Fission Uranium Acquisition Is Under National Security Review

8. okt 2024, 22:37 UTC

Omandamised, ülevõtmised, äriostud

Paladin: Fission Uranium Acquisition Still Requires Clearance Under Investment Canada Act

8. okt 2024, 22:36 UTC

Omandamised, ülevõtmised, äriostud

Paladin: Canadian Court Approves Acquisition of Fission Uranium

8. okt 2024, 22:34 UTC

Market Talk

Pro Medicus Doing Well But Some Concerns Remain -- Market Talk

8. okt 2024, 22:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. okt 2024, 22:28 UTC

Market Talk

Infratil's CDC Valuation Could Be Conservative -- Market Talk

8. okt 2024, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Woodside Says Driftwood LNG Project Renamed Woodside Louisiana LNG

8. okt 2024, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Completes Acquisition of Tellurian

8. okt 2024, 21:42 UTC

Peamised uudised

Federal Deficit Hit $1.8 Trillion for 2024, CBO Say -- 3rd Update

8. okt 2024, 21:26 UTC

Peamised uudised

Hurricane Milton Might Distort Economic Data. GDP Could Take a Hit. -- Barrons.com

8. okt 2024, 21:17 UTC

Peamised uudised

GM Met With Investors Tuesday. The Car Business Is Better Than Many Fear. -- Barrons.com

8. okt 2024, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

8. okt 2024, 20:54 UTC

Peamised uudised

Fed's Collins Sees More Rate Cuts Ahead to Freeze the Economy Where It Is Now -- Barrons.com

8. okt 2024, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. okt 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. okt 2024, 20:18 UTC

Peamised uudised

S&P Gains; Tumult Grips Chinese Stocks -- WSJ

8. okt 2024, 20:00 UTC

Peamised uudised

Federal Deficit Hit $1.8 Trillion for 2024, CBO Say -- 2nd Update

8. okt 2024, 19:35 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

8. okt 2024, 19:07 UTC

Market Talk

Oil Futures Give Back Gains as Risk of Supply Disruption Eases -- Market Talk

8. okt 2024, 18:43 UTC

Peamised uudised

Fed's Bostic Eyes Hurricane Fallout as Economic Risks Remain Balanced -- Barrons.com

8. okt 2024, 18:42 UTC

Peamised uudised

Federal Deficit Hit $1.8 Trillion for 2024, CBO Says -- Update

8. okt 2024, 18:31 UTC

Tulu

GM Stock Rises After Management Provides Some Insight Into 2025 -- Barrons.com

8. okt 2024, 18:29 UTC

Tulu

Hot Research: 6 Stocks That Can Pop in a So-So Earnings Season -- Barrons.com

8. okt 2024, 18:28 UTC

Tulu

Decision Time for GM in China: Stay, Scale Back or Go -- Update

Võrdlus sarnastega

Hinnamuutus

ADMA Biologics Inc Prognoos

Hinnasiht

By TipRanks

-6.71% langus

12 kuu keskmine prognoos

Keskmine 19.33 USD -6.71%

Kõrge 20 USD

Madal 18 USD

Põhineb 3 Wall Streeti analüütiku instrumendi ADMA Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi ADMA Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

19.8 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

There are no events.

All events are bullish.

Sentiment

By Acuity

55 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.